2012, A NEW MOMENTUM FOR THE CANCÉROPÔLE LYON AUVERGNE RHÔNE-ALPES

As a leading research cluster in supporting the creation and advancement of large-scale projects in oncology, the Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA), has strengthened its commitment, all through 2012, to the members of its network, at the institutional level and by the deployment of its programs.

As CLARA reaches its 10th anniversary and a new Cancer Plan is on the horizon, the CLARA executive leadership sought to breathe new energy into the organization and offer fresh perspectives. In an economic climate requiring that every outlay proves as cost effective as possible, CLARA had to solidify its position to ensure that researchers, clinicians, and industry professionals in Oncology have the best chance of success and that patients receive the finest care.

Therefore, an Executive Steering Committee was formed in 2012 to assist CLARA in moving toward a “Network of Networks in Oncology”, enhancing CLARA’s capacity to bring together all the stakeholders in Clermont-Ferrand, Saint-Étienne, Grenoble and Lyon.

The year 2012 also saw the development of official ties with the competitiveness cluster Lyonbiopôle. The objective is twofold: converge the two clusters’ methods of fostering the emergence of innovation and accrediting R&D projects as well as assist in achieving optimal knowledge transfer and exploitation of research results to create clinical applications.

Given the historic missions of CLARA to lead and organize Oncology Research, it is now taking a major step forward in broadening its support of emerging themes (Human, Economic and Social Sciences, Environment, Nutrition) by helping them build strong scientific foundations and tackle the new challenges in the fight against Cancer.

For 2013, CLARA’s path is clear and has four objectives:

- Transform CLARA into a “Network of Networks in Oncology” to foster dialogue between all stakeholders
- Offer an interregional scientific strategy that integrates basic and clinical research
- Address the issue of inequity in our approaches to Cancer by fleshing out the emerging themes in Oncology that are now at the center of patient lives and cause for societal concern
- Develop closer ties with Lyonbiopôle to improve the regional innovation ecosystem.

Working together will get us farther down the road to Cancer Research.

Véronique TRILLET-LENOIR
President,
Management Committee

Amaury MARTIN
Secretary General

Progress Report 2012
CLARA's Missions

A NETWORK OF NETWORKS FOR ADVANCING CANCER RESEARCH

Since its creation in 2003 as part of the first Cancer Plan, the Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA) has been uniting and leading a network associating academic, clinical and industrial strengths in Cancer Research in Rhône-Alpes Auvergne.

Mandated to organize Oncology Research, CLARA is one of the key stakeholders involved in innovative projects that focus on the quick exploitation of research results for the direct benefit of patients.

Supported by the French National Cancer Institute (INCa) and 14 local authorities, CLARA is working to promote interregional strengths on the national and international stages and contribute to economic growth in the Rhône-Alpes and Auvergne regions.

CLARA’S GOALS

> Consolidate a network of experts to accelerate Cancer Research
> Support the clinical development of innovative projects
> Reinforce national and international collaborative dynamics to increase the participation of research teams in ambitious programs
> Fully engage in global Cancer efforts by partnering with Lyonbiopôle with the support of local authorities
> Speed up the creation of companies, their growth, and their interregional establishment

CLARA: Network of Networks in Oncology in Rhône-Alpes and Auvergne

More info on www.canceropole-clara.com
CANCER RESEARCH IN RHÔNE-ALPES AND AUVERGNE

> **M18€** received by research teams for 130 projects*

> **1500** active researchers**

> Second region in France in the publication of scientific papers

  - **15%** of French publications in Oncology (Ile-de-France 36%)*
  - **20%** of leading publications (Top 1%) (Ile-de-France 45%)**
  - **17%** of high-profile publications (Top 10%) (Ile-de-France 37%)**

> A network of top researchers with outstanding results after the INCa 2012 call for projects, especially in clinical research and emerging themes

  - **23%** of projects in the Clinical Cancer Research Hospital Program (PHRC)
  - **20%** of projects in Human and Social Sciences, Epidemiology and Public Health
  - **20%** of projects in Intervention Research and Reduction of Social Inequalities

* See details on projects in the appendix

** Sources: Thomson Reuters WoS (January 2012); Bibliometric Analysis of Cancer Research: A National Inter-Cancéropôle/INCa Study (July 2012) (“active” refers to author or coauthor of at least three publications between 2006 and 2011)

*** Source: Press Index (print media only)

---

CANCÉROPÔLE LYON AUVERGNE RHÔNE-ALPES

> Reinforced influence

  - **1500** people involved in **31** scientific events
  - **79** press releases***

> Increased support for emerging innovation in 2012

  - **€425,000** allocated by CLARA to 18 projects*
  - **10** OncoStarter* projects to ensure sustained project development
  - **8 mobility grants** to help young researchers

> Proof of Concept program since 2007

  - **32** projects supported, **15*** in progress and **5** in post-closure follow-up
  - **€25,1M** invested by interregional business partners
  - **€12,2M** allocated by local authorities and the European Regional Development Fund (ERDF)

> Concrete results

  - 1 robotic surgical device on the market
  - 5 clinical development projects
  - 6 preclinical assessments performed
Structuring of Research

Scientific animation is a top priority for CLARA and part of an overall strategy of supporting activities in key themes and stimulating the development of partnerships between network members and beyond.

The events organized or supported in 2012 have made it possible to reinforce interregional interaction, thus enriching the research landscape with new projects, new innovations, and many thematic collaborations.

As a network leader that knows how to mobilize interregional expertise and assets, CLARA has directly supported several events. Selected according to their alignment with the Cancer Plan priorities, these events offer opportunities for the network to build better targeted relationships and promote scientific culture.

**KEY FIGURES 2012**

- 16 events
- €400,000 annual budget
- €30,000 allocated to 9 events
- 1500 people mobilized

**SPOTLIGHT ON...**

7TH SCIENTIFIC FORUM

The flagship CLARA event, the 2012 edition offered:

- Theme day on innovative approaches to combating Cancer with monoclonal antibodies (partnership with Lyonbiopôle)
- All-day meeting of interregional actors in Cancer Research, allowing them to present their ongoing works and discuss the most recent advances in basic, clinical and translational research in thematic sessions, in partnership with national and international organizations
- Satellite event on Nanomedicine and Oncology in Rhône-Alpes Auvergne and Catalonia (in partnership with the Biocat cluster)

Internationally renowned speakers came together to bring the theme beyond interregional borders (20% of participants from outside the interregional area) and allow the development of partnerships in the study of monoclonal antibodies.

Janice REICHERT, Center for the Study of Drug Development, Tufts University, invited speaker of the 7th CLARA Scientific Forum

More info on www.canceropole-clara.com
HIGHLIGHTS 2012

January
- Open meeting on Nanotechnologies, Imaging and Cancer - Presentation of projects and networking

February
- Inter-Cancéropôles conference Glioblastoma: Molecular and Cellular Characterization and Preclinical Models, Marseille

March
- 7th CLARA Scientific Forum, Lyon
- 30th meeting of the Club for the Study of Epithelial Cells of the Digestive Tract (CECED), Grenoble

April
- 4th Inter-Cancéropôles Workshop on Bioinformatics, Nice

May
- Workshop on Geographical Approaches to Evaluating Exposure to Pesticides, Lyon
- 6th Francophone Conference on Clinical Epidemiology (EPICLIN) / 19th Statistician Forum of the Centers for the Fight Against Cancer, Lyon
- 3rd edition of Courir Pour Elles, (Women’s Run Against Breast Cancer), Lyon/Domaine de Lacroix Laval

June
- Cancer Cells On-Chips: Now and the Future, Lyon
- Association des Neuro-Oncologues d’Expression Française (ANOCEF), [French association for neuro-oncology and gene expression], Clermont-Ferrand
- 8th Annual Forum of the French Sarcoma Group – Bone Tumor Study Group, Lyon

September
- 5th Inter-Cancéropôles Bioinformatics Workshop, Lyon

October
- 2nd Translational Research Meeting, Gerland Lyon-Sud

November
- 12th International Conference on Cancer-Induced Bone Disease, Lyon
- 2nd Franco-Chinese Symposium on Oncology Research, Lyon

December
- 11th LOWRAD International Conference, Lyon

CLARA’S MISSIONS

Cancerology Community
Researchers, Industrials, Clinicians...

Research Projects in Cancerology

Interregional Community Animation
Research support
Expertise and Projects Follow-up
Financing

> Scientific and Therapeutic Innovations for Patients
> Territorial Economic Development

Organizer or co-organizer
Funding
Institutional partner
Entrusted by local authorities to play a key role in stimulating economic growth, CLARA organized several scientific events in 2012 related to the exploitation of research results in order to promote the transfer of results to industry and patient care. Whether in the form of webinars, training sessions, workshops or meetings, the objective is to expand the expertise of the network and help build partnerships between industry and academics.

HIGHLIGHTS 2012

April
• Webinar Knowledge Transfer and Exploitation of Research Results in Oncology: Understanding the CLARA Proof of Concept

July
• Workshop on Industrial Property and Innovation Strategy (Part 1), Lyon*

September
• Webinar Rare Cancers as Models for Clinical Proof of Concept for Innovative Cancer Treatments
• Educational Session of the CLARA Regulatory Unit Cancer Vaccines, Lyon
• Workshop on Industrial Property and Innovation Strategy (Part 2), Lyon*

October
• Education: CLARA-MATWIN Proof of Concept Training Introduction to Drug Discovery: From the Lab to Early Clinical Use, Lyon
• Workshop on Industrial Property and Standards, Lyon*

November
• Workshop on Protecting Combination Products in Healthcare: Biotechnology Inventions – Medical Devices, Lyon*

December
• Workshop on Technology Forecasting and Competitive Intelligence in R&D Projects, Lyon*
• 5th CLARA Industrial/Academic Encounters, Lyon*

Organizer or co-organizer

* Part of the industrial property awareness program set up by the French National Industry Property Institute (INPI), Lyonbiopôle, I-Care Cluster and CLARA (see spotlight on page 9)

SPOTLIGHT ON...
TRAINING SESSION INTRODUCTION TO DRUG DISCOVERY: FROM THE LAB TO EARLY CLINICAL CARE, LYON

Organized by CLARA and MATWIN SAS, this training day was specifically addressed to CLARA Proof of Concept and MATWIN 2012 project leaders.

Intended to meet the needs of academic researchers who want to pursue their work continuously until proof of concept and beyond until transfer to industry and clinical care, the purpose of this two-session training program was to raise awareness of the specific issues and challenges inherent in development.
**SPOTLIGHT ON… 5TH CLARA INDUSTRIAL/ACADEMIC ENCOUNTERS**

This key annual event brings together actors in Oncology Research and development in Rhône-Alpes and Auvergne. In 2012, the CLARA Industrial/Academic Encounters offered opportunities for face-to-face meetings between established and potential partners (like a business convention) as well as a plenary session on the complementary strengths of engineering sciences and Oncology, underscoring technological and clinical challenges and opportunities.

Special focus was given to the high potential for innovation through a combined approach encompassing engineering and Cancer Research. Participants learned of the conclusions reached by a joint CLARA and I-Care Cluster scientific committee which organized discussions throughout the year among representatives from medicine, research and business.

During this event, two high-potential projects received the CLARA 2012 Trophies:

- **Development of Functional Fluorescent Nanoparticles for Detecting Colorectal Tumors** (G. BARABINO and J.-M. PHELIP, LINA EA 462 Laboratory / Jean Monnet University, CHU Saint-Étienne)

- **Transthoracic Therapeutic Imaging Using 3-D Magnetic Resonance Imaging-Ultrasound Hybrid Guidance** (M. VIALLON, P. CROISILLE and S. SALOMIR, CREATIS, University Hospitals of Geneva)

---

**KEY FIGURES 2012**

- **> 10 events** related to technology transfer
- **> €36,000** annual budget dedicated to events related to technology transfer
- **> 400 people** mobilized

---

**SPOTLIGHT ON… WORKSHOPS ON INDUSTRIAL PROPERTY AWARENESS**

First launched in 2008, CLARA partnered in 2012 with the French National Industry Property Institute (INPI), Lyonbiopôle and I-Care Cluster to organize workshops on industrial property awareness.

These workshops are means for any economic and Research actors concerned with protecting industrial innovation as a differentiating factor in competitiveness and growth.

---

**THEY TALKED ABOUT IT…**

Encounter with Gabriele BARABINO, Jean-Marc PHELIP and Michèle COTTIER, CLARA Trophies 2012

“CLARA is a strong element of motivation and structuring within our team and projects and is important in connecting us to the outside world. Besides our respective activities, CLARA is the motherhouse of our NANOCOLON project.”

---

Read their complete comments on…

[www.canceropole-clara.com](http://www.canceropole-clara.com)

---

The CLARA team thanks all the participants in the study groups as well as the experts who attended the events, most notably Jean-Jacques ZEILLER and Jacques DESCOTES.
Recognizing the importance of the human, economic and social sciences in basic and clinical research, CLARA supported the expansion of the working group in 2012 in order to welcome new actors.

To achieve regional and national visibility, several high-priority themes were selected regarding:

- Prevention
- Social inequalities
- Doctor-patient relationship
- Healthcare management
- Technological developments
- Epidemiological indicators

At the crossroads of the issues of personal risk, lifestyle and environmental and community risks for the individual, the Human, Economic and Social Sciences focus area of CLARA can spearhead or advance Research involving basic and applied disciplines.

**HIGHLIGHTS 2012**

**September**
Support provided to three new OncoStarter projects in this area

- **RI-SCOLAIRe** aims at implementing intervention Research on identifying and preventing Cancer in school environment
- **DEDEPRO** has set out to adapt, implement and assess information and decision-support tools for prostate cancer screening with prostate-specific antigen testing
- **INEGO** is studying factors contributing to inequalities in initial management of ovarian epithelial cancer in France between 2011 and 2014

**December**
Opening of the Hygéée Center, a regional Cancer prevention center and public health platform in Saint-Etienne

**KEY FIGURES 2012**

- **1st French Cancéropôle in Social Sciences related to Oncology**
- **90 researchers**
- **20 research teams**
- **15 laboratories** evaluated by AERES, including 9 rated A+ and A*
- **3 OncoStarter projects** launched in 2012
- **20% of projects** funded by INCa in the Human and Social Sciences, Epidemiology and Public Health are CLARA projects

*June 2012: Overview of the interregional driving forces in Rhône-Alpes Auvergne in human and social sciences, under the supervision of L. DIXON (CLARA internal data)

**January 2012: Thomson Reuters WoS: July 2012: Bibliometric Analysis of Cancer Research: A National Inter-Cancéropôles/INCa Study**

More info on www.canceropole-clara.com
SPOTLIGHT ON...
HUMAN AND SOCIAL SCIENCES
WORKING GROUPS LED BY INCa

Working group on
Quality of Worklife,
Quality of Care, Patient
Quality of Life

- Promoting and assisting the emergence of national research projects through open calls for projects in Human and Social Sciences, Environment and Public Health
- Helping determine research prospects in calls for projects in Human and Social Sciences, Environment and Public Health

INCa Inter-Cancéropôles Working group on Inequality and Intervention Research

- Helping determine research prospects in calls for projects in Human and Social Sciences, Environment and Public Health
- Assisting the completion of national research projects resulting from calls for projects

Contact: Véronique REGNIER (Hygée Center, Saint-Étienne)

---

SPOTLIGHT ON...
HYGÉE: REGIONAL CENTER FOR CANCER PREVENTION

The Hygée Center, the CLARA regional public health platform, is housed in a 2500 square-meter building near the Loire Cancerology Institute and is divided into three operational divisions:

- Health education division focused on Cancer prevention activities (primary, secondary and tertiary) for the general public
- Cancer treatment and Research education division
- Public health Research division to raise regional awareness of Cancer and Cancer-related issues

This Center represents an investment of €9M, provided by the French government, the Rhône-Alpes Region, the Loire County, Saint-Étienne Métropole and the Loire Cancerology Institute.

First French Cancéropôle in scientific publications

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CLARA</td>
<td>1,36</td>
</tr>
<tr>
<td>IDF</td>
<td>1,2</td>
</tr>
<tr>
<td>NO</td>
<td>0,87</td>
</tr>
<tr>
<td>INCa</td>
<td>0,82</td>
</tr>
<tr>
<td>GE</td>
<td>0,78</td>
</tr>
<tr>
<td>GSO</td>
<td>0,66</td>
</tr>
<tr>
<td>GO</td>
<td>0,57</td>
</tr>
</tbody>
</table>

> Specialization index for Cancéropôles in publications in social sciences
> Values greater than one indicate the Cancéropôle is more specialized in the field than average in France.

The CLARA team thanks Lucette DIXON for her valuable input regarding the human and social sciences focus area and proposals for evolution.
In response to the priorities of Cancer Plan II (measure 3), CLARA has incorporated an Environment, Nutrition and Cancer focus area into its 2011-2014 program. Expanded from the thematic focus area Nutrition and Cancer developed between 2007 and 2010, it aims to promote interdisciplinary Research in a field that has regional and national visibility and to contribute to improving knowledge of risk factors:

- Environmental (pesticides and nanomaterials)
- Nutritional (metabolic mechanisms and preventive nutrition interventions)

**SPOTLIGHT ON… INCa WORKING GROUP ON NUTRITION**

Developing a National Cancer Nutrition Research Network (NACRe) and CLARA national expertise in Nutrition and Cancer to:

- Promote and assist the emergence of national research projects
- Help determine research prospects

Contact: Marie-Paule VASSON, (Faculty of Pharmacy, University of Auvergne)

**EMERGING THEMES**

**ENVIRONMENTAL AND NUTRITIONAL FACTORS IN ONCOLOGY: PROMOTING INTERDISCIPLINARY RESEARCH THAT ACHIEVES NATIONAL VISIBILITY**

**KEY FIGURES 2012**

- 4 OncoStarter projects
- 3 workshops (pesticides, nanomaterials and nutrition)
- 3 meetings of the INCa Working Group

**HIGHLIGHTS 2012**

**February**

Launch of the OncoStarter project EXPO-NANO

Coordinated by Jean-Michel VERGNON (CHU Saint-Étienne) and Jérémy POURCHEZ (Saint-Étienne School of Mines), the goal of this project is to develop an indicator of exposure to nanoparticles in order to monitor people who are at occupational risk.

**May**

Workshop on Geographical Approaches to Evaluating Exposure to Pesticides at the International Agency for Research on Cancer (IARC) and Léon Bérard Cancer Center, Lyon

**July**


**September**

Launch of three new OncoStarter projects, including:

- GEO3N on environmental exposure to dioxins and the risk of breast cancer
- CASTA on breast cancer and obesity

**November**

INCa/National Cancer Nutrition Research Network (NACRe) Nutrition and Cancer Forum (Before, during, after)

More info on www.canceropole-clara.com
In 2010, with the support of the pharmaceutical company Merck Serono, CLARA awarded the Chair of Excellence in “Environment, Nutrition and Cancer” to Dr Béatrice FERVERS of the Cancer and Environment Unit of the Léon Bérard Cancer Center. During those three years, Dr FERVERS has led two major research projects:

• **Detecting occupational cancer**, in collaboration with the Consultation Center for Professional Pathologies, the occupational health center of the Lyon Civil Hospitals. Aiming to improve patient education and overall patient care, this work received the label “Année des patients et de leurs droits” [year for patients and their rights] in 2011.

• **Study of environmental and nutritional factors in breast cancer** taking two complementary approaches:
  - Study of the cellular, biochemical and genomic impact of chronic low-dose exposure to substances that disrupt endocrine function
  - Randomized clinical study of the changing metabolic and cytokine profiles in women diagnosed with breast cancer participating in a six-month nutrition program (diet and exercise) concomitant with cancer treatment

A public informational web portal on exposure to risks related to the environment, workplace and personal behavior was also created. Its objective is to provide scientifically sound public health information.

[www.cancer-environnement.fr](http://www.cancer-environnement.fr)
Eager to incorporate its actions into a national approach that includes interregional teams, CLARA is actively participating in national INCa working groups and creating close ties with partner networks by embracing their initiatives.

**VIRTUAL MICROSCOPY**

Inter-Cancéropôles Working group aiming to:
- Share information and know-how for cross-fertilization between Research-Clinical Care-Education approaches
- Issue recommendations that could become INCa recommendations
- Offer an international organization that works with business

Contact: David MEYRONET (CHU Lyon)

**BIOINFORMATICS**

Organizing top-tier inter-Cancéropôles scientific animation around the Bioinformatics platform of the Synergy Lyon Cancer Foundation and as part of the International Cancer Genome Consortium.

The themes covered in 2012 in the half-yearly workshops were:
- New generations of sequencing applied to Cancer transcriptomics
- High-throughput epigenomics

Contact: Gilles THOMAS (UCBL, Synergy Lyon Cancer Foundation, CLB)
CLINICAL RESEARCH

Putting the Clinical Cancer Research Support Platform of the Auvergne Rhône-Alpes (PARCC-ARA) region at the center of the activities of the INCa working group to:

- Increase the potential of clinical Cancer Research by helping investigators design, coordinate and analyze their clinical studies
- Improve INCa clinical trials registry data
- Guide actors involved in local clinical research on clinical trials
- Identify what determines the supply, demand, needs and conduct of Cancer clinical trials, especially when they are associated with inequalities

Contact: David PEROL (CLB, CRCL, PARCC-ARA)

HIGHLIGHTS 2012

April
4th Inter-Cancéropôles Bioinformatics Workshop, Nice

May
19th Statistician Forum of the Centers for the Fight Against Cancer and 6th Francophone Conference on Clinical Epidemiology (EPICLIN), Lyon

September
5th Inter-Cancéropôles Bioinformatics Workshop, Lyon
STRUCTURING OF RESEARCH

INTERNATIONAL: POSITIONING THE RHÔNE-ALPES AND AUVERGNE REGIONS AS EUROPEAN REFERENCE SITES IN THE FIGHT AGAINST CANCER

Aware of the importance of expanding interregional Research beyond borders, CLARA is actively promoting international collaborations through two close partnerships:

- With Spanish Cancer Research clusters (Catalonia and Castilla y Léon)
- Between authorities in Shanghai and the Rhône-Alpes Region.

KEY FIGURES 2012

- > 20 European projects in progress, representing a budget of close to €100M
- > 2 strong collaborations: Shanghai and Spanish clusters
- > 1 student (Master 2 (Bologna Process), then Ph.D. thesis) pursuing a joint University of Lyon/Shanghai University degree

IN THEIR WORDS...

Encounter with Dr Véronique MAGUER-SATTA, ROBACETIC project

“CLARA has supported us at every stage of this international project, which would not exist without it. In a word, CLARA allowed us to have a vision”

HIGHLIGHTS 2012

January
Biotech cluster’s visit to CLARA: Launch of a French-Spanish, inter-cluster collaboration

March
Satellite event of the 7th Scientific Forum on Nanomedicine and Oncology in Rhône-Alpes Auvergne and Catalonia, in partnership with the Biocat cluster

November
2nd Franco-Chinese Symposium on Cancer Research, in partnership with the Rhône-Alpes Region

IN THEIR WORDS...

Encounter with Dr Véronique MAGUER-SATTA, ROBACETIC project

“CLARA has supported us at every stage of this international project, which would not exist without it. In a word, CLARA allowed us to have a vision”

More info on www.canceropole-clara.com
SPOTLIGHT ON…
COLLABORATION WITH SPANISH ONCOLOGY CLUSTERS

In an effort to give a prominent European dimension to the Rhône-Alpes Auvergne interregional Oncology cooperation, two firm partnerships were forged in 2012 with the Biotecyl and Biocat Spanish clusters.

The collaboration with the Biotecyl cluster (Salamanca, Castilla y Léon) is developing a joint work plan whose areas of Research relate to new therapeutic approaches, personalized medicine and biomarkers in sarcomas and leukemia. CLARA invited the Spanish Research leaders to visit Lyon in January to prepare an application for an Interreg program.

As part of the 7th CLARA Scientific Forum, a satellite event was organized with the Biocat cluster (Catalonia) on Nanomedicine and Oncology in Rhône-Alpes Auvergne and Catalonia. Ten researchers, clinicians and CEOs were invited to share their activities with regional actors in order to develop partnerships.

SPOTLIGHT ON…
2ND FRANCO-CHINESE SYMPOSIUM ON CANCER RESEARCH

Since 2011 and thanks to the support of the Rhône-Alpes Region, CLARA is leading an ambitious program of collaboration between academic teams in the region and their counterparts in Shanghai.

The visit of a French delegation to Shanghai in July 2011 resulted in the first collaboration, which focuses on stem cells (breast and prostate cancer), between Prof GAO (Med-X Renji Hospital, Stem Cell Research Center) and Dr MAGUER-SATTA (Cancer Research Center of Lyon).

To increase momentum, a delegation of Chinese researchers and institutional representatives was received in Lyon in November 2012. The goal was to improve mutual understanding of the two countries’ approaches to the management of Cancer Research and care, present the results of the first joint projects and initiate and strengthen collaborative efforts.

Several partnerships are now being set up.
Supporting Research Projects

MOBILITY: BUILDING TOMORROW’S TALENT

Mobility for young researchers is a source of acquiring new techniques and knowledge and promotes the emergence and strengthening of collaborative projects. For this reason, CLARA set up a program in 2011 focusing on mobility.

Intended for young researchers in Rhône-Alpes Auvergne involved in Oncology projects requiring regional, national or international travel lasting between one and three weeks, the CLARA Mobility program can assist with funding up to €2,500.

EXAMPLES OF 2012 PROJECTS

> Étude des instabilités génétiques des dysplasies pré-cancéreuses tubo-ovariennes chez les patientes à risque génétique (Jean Perrin Cancer Center, Clermont-Ferrand ➔ Montreal University Hospital, Canada)

> Étude de la Caséine Kinase 2 et de ses inhibiteurs ; cytotoxicité vis-à-vis de cellules tumorales pancréatiques (Claude Bernard Lyon 1 University ➔ CEA of Grenoble)

> Impact des expositions environnementales prénatales sur l’incidence du cancer du testicule (IARC ➔ Danish Cancer Society, Karolinska Institute, Sweden)

The complete list of projects appears in the appendices (see p. 28)

KEY FIGURES 2012

> €20,000 allocated

> 8 grants for Mobility

Geographic Origin of Selected Mobility Projects

- Lyon 87%
- Clermont-Ferrand 13%

Destination of Selected Mobility Projects

- International 38%
- Within CLARA Perimeter 37%
- National 25%
Since 2011, thanks to its unique position allowing it to speed up project development to maximize chances of receiving later funding, OncoStarter complements traditional project development systems as well as, among others, CLARA Proof of Concept and INCa calls for projects.

In addition to financial assistance allocated to solidify scientific data, teams can receive personalized coaching to raise the level of quality of their projects (extension of partnerships, market research, consideration of regulatory issues, etc.).

Open to all Translational Research projects as well as those that fall within emerging themes identified by CLARA (Assessment, Perception of Risks and Cancer Prevention, Environment, Nutrition and Cancer), it promotes the development of multidisciplinary approaches.

KEY FIGURES 2012

> €405,000 alllocated
> 8 projects chosen
• 3 projects in Translational Research
• 5 projects in Environment, Nutrition, and Human and Social Sciences

EXAMPLES OF 2012 PROJECTS

Translational Research
> Potentialisation des traitements des cancers du pancréas
> Nouveau marqueur pronostic et prédictif du cancer du sein ER+
> Développement de nanoparticules fluorescentes pour la détection des lésions tumorales colorectales

Emerging Themes
> Représentations et prévention des cancers en milieu scolaire
> Évaluation d’outils d’information et d’aide à la décision dans le dépistage du cancer de la prostate
> Facteurs d’inégalités de la prise en charge initiale des cancers épithéliaux ovariens
> Vers un indicateur d’exposition aux nanoparticules
> Expositions environnementales aux dioxines et risque de cancer du sein

The complete list of projects appears in the appendices (see p. 28)

In 2012, top priority was given to supporting projects on emerging themes: Environment, Nutrition, Human and Social Sciences

Balanced location-based projects

30% Translational Research
70% Emerging Themes
1% Grenoble
3% Saint-Étienne
5% Lyon
1% Clermont-Ferrand
Supporting Research Projects

CLARA PROOF OF CONCEPT: A KEY STEP IN REACHING CLINICAL CARE FASTER

Since 2005, CLARA has been running a unique and powerful program for exploitation of research results: the Proof of Concept program.

Through financial support and assistance to academic and clinical teams in Rhône-Alpes Auvergne, this program makes it easier to develop preclinical projects and clinical studies on high-potential product candidates (drugs and devices) and generate industrial property to support them.

In partnership with a company working within CLARA’s scope of activities that is conducting and committed to exploiting the research results in the long run, the program focuses on local economic growth and contributes to promoting innovative therapeutic and diagnostic solutions that directly benefit patients.

KEY FIGURES 2012

> 1 robotic surgical device on the market
> 5 projects in clinical development
> 6 preclinical assessments performed
> 32 projects supported, including 15 in progress and 5 in post-project follow-up**
> €37.3 M overall budget (€25.1M invested by interregional business partners and €12.2M by local authorities and ERDF)
> More than 70 partners, including 7 clinical centers
> 41 scientific publications*
> 43 scientific press releases*
> 25 patent applications*

* Based on data available on December 31, 2012
** Projects are described in the appendix (see p. 29)

More info on www.canceropole-clara.com
HIGHLIGHTS 2012

January
Synfrizz launches its phase 1 clinical trial first in man/first in class to develop a new treatment for synovial sarcoma. Based on an innovative treatment combining anti-FZD10 antibody with radiation therapy, it is the first targeted treatment in the world for this type of Cancer. The trial will take place for 24 months and involve 21 sarcoma patients in three French Cancer centers.

May
Creation of Anastom Surgical as part of the UroLink project. Led by Arnold FERLIN, the company Anastom Surgical is the business partner in the UroLink project whose goal is to develop automated urethrovesical anastomosis for prostate cancer. Spawned from the technology incubator CREALYS, Anastom Surgical is the 2012 laureate of the 13th Tremplin Entreprise [Business Springboard] co-organized by the French Senate and ESEC.

June
The Enki-HEH project starts clinical trials at the Lyon Civil Hospitals to test a new tumor resection technique that uses a pulsed jet of water.

July
A study of high-intensity focused ultrasound (HIFU) begins the phase 2b clinical trial stage for the treatment of hepatic metastases. Launched in 2011, phase 2a clinical trials were approved in February 2012 by a committee of experts. The approvals for moving to phase 2b by the institutional review board (CPP) and French Agency for Health Product Safety (ANSM) were granted in summer 2012. The first three patients were enrolled in September 2012. The procedures for obtaining CE marking were initiated in December 2012.

August
GeniusVac-Mel4 requests approval of a phase 1 clinical trial. The objective of the project is to develop an innovative drug treatment (cell therapy) for melanoma. After receiving a positive response from CPP in October 2012, feedback from ANSM is expected in 2013.

September
Reception of nine letters of intent as part of the 8th CLARA Proof of Concept call for projects (six applications assessed)

November
HepatoFluo received approval to start its phase 1 clinical trial. Based on Fluobeam™ technology from the company Fluoptics, the objective of the HepatoFluo project is to assess the feasibility and effectiveness of a fluorescent marker in improving surgical procedures for hepatic metastases and primary liver cancer. Patient enrolment will begin in January 2013. The device received CE marking in December 2012.

The complete list of projects appears in the appendices.
Supporting Research Projects

MAJOR INTERREGIONAL PROJECTS: ENHANCING THE REPUTATION OF THE TERRITORY IN ONCOLOGY

Emphasizing the importance of making sure that interregional research teams join forces in innovative and competitive projects that address national Cancer Research priorities and favorably position interregional teams in Europe, CLARA and local authorities have partnered since 2009 to implement a strategy of providing maximum support to development projects.

Sponsor of leading cooperative groups, such as the European Lymphoma Institute (ELI) and World Sarcoma Network (WSN), CLARA decided this year to fund a chair of excellence in Translational Research in Oncology in Grenoble.

ELI
EUROPEAN LYMPHOMA INSTITUTE

Uniting the most prominent lymphoma specialists in Europe in an institute dedicated to Research, training and education, ELI’s goal is to determine a strategy, therapeutic and diagnostic standards and facilitate basic and clinical Research in Europe.

Using this one-of-a-kind collaborative operating model, ELI wants to advance lymphoma Research to offer all patients equal access to the best care.

Contact: Bertrand COIFFIER (CHU Lyon)

CHAIR OF EXCELLENCE IN TRANSLATIONAL RESEARCH IN ONCOLOGY IN GRENOBLE

In 2012, CLARA, CHU Grenoble, Joseph Fourier University, Isère County, Grenoble Alpes Métropole and the City of Grenoble co-funded a chair of excellence in Translational Research.

Associated with the creation of a laboratory and dedicated team at the Albert Bonniot Institute, this chair of excellence aims to mobilize the driving forces in Grenoble to collaborate with pharmaceutical companies to develop innovative applications.

Contact: Christian BRAMBILLA (Albert Bonniot Institute, Grenoble)

Lymphoma: 6th Highest Incidence of Cancer in the World

Source: INCa Situation du Cancer en France en 2012

More info on www.canceropole-clara.com
KEY FIGURES 2012

> €900,000 over 3 years to ELI and WSN
> €600,000 over 3 years for the chair of excellence in Translational Research
> 6 preclinical assessments performed
> 1 Japanese company working in Lyon thanks to higher visibility through WSN
> + 80% growth rate for research partnerships in 2011 at CALYM (Carnot Lymphoma Institute)

WSN
WORLD SARCOMA NETWORK

The rarity of sarcoma makes clinical Research and trials difficult to conduct. Faced with this challenge, the objective of the World Sarcoma Network is to combine expertise from around the world (13 members) and provide the critical mass of patients for clinical Research.

WSN is a key player in the advancement of Research and is contributing to making the Lyon area increasingly attractive to pharmaceutical companies that want to develop innovative treatments for sarcoma.

Contact: Jean-Yves BLAY (Léon Bérard Cancer Center)

Lyon: Pilot center of the NetSarc network of clinics, the French branch of WSN on soft tissue and visceral sarcomas
Clermont-Ferrand, Expert Center

Contact:
Jean-Yves BLAY
Lyon: Pilot center of the NetSarc network of clinics, the French branch of WSN on soft tissue and visceral sarcomas
Clermont-Ferrand, Expert Center

WSN WORLD SARCOMA NETWORK

The rarity of sarcoma makes clinical Research and trials difficult to conduct. Faced with this challenge, the objective of the World Sarcoma Network is to combine expertise from around the world (13 members) and provide the critical mass of patients for clinical Research.

WSN is a key player in the advancement of Research and is contributing to making the Lyon area increasingly attractive to pharmaceutical companies that want to develop innovative treatments for sarcoma.

Contact: Jean-Yves BLAY (Léon Bérard Cancer Center)
Supporting Research Projects

FUNDING OF PROJECTS WITHIN CLARA’S PERIMETER: MEASURABLE IMPACT ON THE STRENGTH OF ONCOLOGY RESEARCH

N° 2 area in France in Oncology Research, the Rhône-Alpes Auvergne inter-region is receiving strong support from all funding sources, from non-profit organizations to public institutions. The projects are detailed in the appendix.

THE LEAGUE AGAINST CANCER

€2,3M granted to CLARA research teams:
  > Accredited research teams (7 teams, €736,000)
  > Regional clinical research platform (1 platform, €120,000)
  > Clinical research project (1 project, €100,000)
  > Projects in Human and Social Sciences (3 projects, €124,000)
  > Adolescents and Cancer program (2 recipients, €48,000)
  > Research allocations (34 recipients, €1.2M)

Note that these figures do not include funding from French county committees because data was unavailable at the time of publication of this document.

KEY FIGURES 2012

> €18M obtained by research teams*
> 130 projects*
> 1500 active scientists

* Not including OSEO and Investments for the Future

ARC FOUNDATION FOR RESEARCH ON CANCER

€3,2M granted to CLARA research teams:
  > Individual stipends (30 recipients receiving a total of €1.4M)
  > Medium-level equipment (€507,000)
  > Fixed funding (€450,000)
  > Partnered funding of projects from calls for projects
    • NCI/CLIP² (€452,000)
    • PAIR Gynecology (€250,000)
  > Support for innovative therapeutic Research (€166,000)

ITMO CANCER

€1,69M granted to CLARA research teams:
  > Research projects (7 projects receiving at total of €1.5M)
  > Support for Research and training (4 recipients receiving a total of €190,000)

More info on www.canceropole-clara.com
FRENCH NATIONAL CANCER INSTITUTE (INCa)

€10,3M granted to CLARA research teams:

> Research projects (8 projects receiving a total of €4.2M)
> Projects in the Clinical Cancer Research Hospital Program (13 projects receiving a total of €5M)
> Support for organizations, networks and public health actions (7 recipients receiving a total of €1.1M)

FRENCH NATIONAL RESEARCH AGENCY (ANR)

Two CLARA PROJECTS selected in 2012 as part of the call for projects “Research Partnerships and Biomedical Innovation”

> OREGA-17 is developing new interleukin-17 antagonists for use in Oncology. Regional partner and coordinator: OREGA Biotech (amount allocated not available)
> MULTIMAGE is developing nanometer structures for early detection using multimodality imaging. Regional partner and coordinator: Pascal PÉRIAT (amount allocated not available)

OSEO

€40.7M granted to two projects involving CLARA participants

(The share received by teams within CLARA’s perimeter is unavailable)

> TEDAC: As part of OSEO’s Strategic Industrial Innovation program, led by Erytech Pharma, TEDAC focuses on developing innovative enzyme therapies that target the metabolic environment of tumors and on using screening and monitoring tests to provide personalized care to patients with cancers resistant to radiation therapy and chemotherapy.
> C4C: Selected as part of the 2nd call for projects “Structuring R&D Projects” to create the first French technology platform for the industrialization of cell therapies, in partnership with the regional company CellforCure and Lyon Civil Hospitals.

INVESTMENTS FOR THE FUTURE

€89M granted to eight projects involving CLARA participants:

> CAMI (Labex – University of Grenoble): New approaches to Computer-Assisted Medical Interventions (Cancer and others)
> PRIMES (Labex – University of Lyon): Program in Physics, Radiobiology, Medical Imaging and Simulation aimed at developing innovative methods and devices in medical imaging for localizing tumors and fine-tuning treatment
> PHENOCAN (Equipex – University of Lyon): Technology platform project for developing mouse models of cancer
> FRANCE LIFE IMAGING (FLI) (Infrastructures (CEA)): National infrastructure coordinated by the French Alternative Energies and Atomic Energy Commission (CEA) that brings together six large-scale imaging platforms for Research on preclinical and clinical imaging, including archiving and image processing

Non exhaustive list; the share received by teams within CLARA’s perimeter is not available.
Financial Results

FINANCIAL RESULTS 2012*

INCOME

In 2012, the CLARA budget was €5,003,684 received as follows:

> €2,852,422: Local authorities
> €1,416,362: INCa
> €674,000: ERDF
> €60,900: Sponsors and others

EXPENSES

Project funding amounts to €3,776,900 (75% of annual budget), broken down as follows:

> €2,496,000: Support for Proof of Concept projects
> €430,614: Project emergence (Mobility, OncoStarter)
> €329,300: Support for large-scale interregional projects (ELI, WSN, Hygée)
> €318,186: Related costs (consultancy fees and project coaching, salaries)
> €202,800: Support for other research projects and PARCC-ARA

Organizational funding amounted to €795,507 (16% of annual budget), broken down as follows:

> €361,866: Overhead (including local)
> €292,305: Administrative and financial management
> €118,044: Communications (including website redesign, press relations for projects and the promotion of interregional Research)
> €23,293: Network coordination (business travel)

Funding of scientific animation related to technology transfer amounted to €431,277 (9% of annual budget), broken down as follows:

> €395,124: Scientific animation (Scientific Forum, thematic workshops, event organization support and axes animation)
> €36,153: Events related to technology transfer (including the 5th Industrial/Academic Encounters)

*Subject to approval of the 2012 budget by the Board of Directors of the Léa et Napoléon Bullukian Foundation. Payroll is integrated into the various expenditure items based on staff posting.

More info on www.canceropole-clara.com
FINANCING ATTRIBUTED IN 2012 TO RESEARCH TEAMS FROM REGIONS COVERED BY THE CANCÉROPÔLE LYON AUVERGNE RHÔNE-ALPES

 Appendix 1

CLARA

MOBILITY GRANTS

- Étude des instabilités génétiques des dysplasies pré-cancéreuses tubo-ovariennes chez les patientes à risque génétique (mutations BRCA); Coordination: Frédérique PENAULT-LLORCA; Applicant: Gautier CHENE (Jean Perrin Cancer Center, Clermont-Ferrand); Host Organization: Montreal University Hospital Center, Canada; €2,500
- Étude du caractère “Cell Penetrating Peptide” d’un fragment de protéine ayant montré une activité anti-angiogénique chez la souris; Coordination: Florence RUGGIERO; Applicant: Rachel MANUEL (Lyon Functional Genomics Institute); Host Organization: Albert Bonniot Institute; €2,500
- Étude des molécules d’adhérence cellulaire et les cascades de signalisation associées; rôle dans la progression tumorale/ Identification de cibles moléculaires dirigées contre une laminine; Coordination: Patricia ROUSSELLE; Bénéficiaire: Fanny WALTZ (Institute of Biology and Chemistry of Proteins, Lyon); Host Organization: Curie Institute/Pharmacochemistry, Biorganic Chemistry, Vectorization; €2,500
- Étude de la Caséïne Kinase 2 (CK2) et de ses inhibiteurs/Études de cytotoxicité vis-à-vis de cellules tumorales pancréatiques; Coordination: Thierry LOMBERGET; Applicant: Benoît BESTGEN (Claude Bernard Lyon 1 University); Host Organization: CEA Grenoble/Biology of Cancer and Infection Team, IRTSV; €2,500
- Impact des expositions environnementales prénatales sur l’incidence du cancer du testicule/Influence de l’activité professionnelle des parents pendant la grossesse et avant conception sur l’incidence du cancer du testicule chez leurs enfants; Coordination: Beatrice FERVERS - Joachim SCHÜZ; Applicant: Charlotte LE CORNET; International Agency for Research on Cancer (IARC)); Host Organization: Danish Cancer Society, Karolinska Institute (Sweden) and Krefregisteret (Norway Cancer Registry); €2,500
- Acquisition de techniques pour l’étude de mécanismes de régulations transcriptionnelles en lien avec LSD1; Coordination: Jean-Marc VANACKER; Applicant: Julie CARNÉSECCHI (Lyon Functional Genomics Institute, CNRS UMR5242, ENS Lyon); Host Organization: CNRS UMR6293, Clermont University, INSERM U1103 Cézeaux University Complex; €2,500
- Une nouvelle approche dans le traitement du carcinome hépatocellulaire: les inhibiteurs de Poly (ADP-ribose) polymérasases (PARP); Coordination: Alain PUISIEUX; Applicant: Clément ROUSSELLE; Coordination: Curie Institute; €2,500
- Étude de la variabilité génomique conduisant au développement et à la progression du cancer du sein; Coordination: David G. COX; Applicant: Sophie BLEIN (Cancer Research Center of Lyon - Léon Bérard Cancer Center); Host Organization: Imperial College of London; €2,500

ONCOSTARTER - EMERGING THEMATICS

- Expo-Nano Minéralopathologie nanoparticulaire: vers un indicateur d’exposition aux nanoparticules; Coordination: Jean-Michel VERGNON (CHU Saint-Etienne); €50,000; 13 months
- CASTA Cancer du sein en situation d’obésité: interactions potentielles in vitro entre sécrétions adipocytaires et thérapies anticancéreuses ; Coordination : Florence CALDEFIE-CHÉZET (Faculty of Pharmacy - Clermont-Ferrand); €39,000; 13 months
- DEDEPRO Adaptation, implantation et évaluation d’outils d’information et d’aide à la décision dans le dépistage du cancer de la prostate par PSA/APS en France, Suisse et au Canada; Coordination: Nora MOUMJID FERDJÃOUI (University of Lyon); €39,000; 13 months
- GEO3N Expositions environnementales aux dioxines et risque de cancer du sein: étude de faisabilité en région Rhône-Alpes, préalable d’une étude nationale au sein de la cohorte E3N; Coordination: Béatrice FERVERS (Léon Bérard Cancer Center); €49,874; 13 months
- InégO Facteurs d’inégalités de la prise en charge initiale des cancers épithéliaux ovariens en France entre 2011 et 2014; Coordination: Isabelle RAY-COQUARD (Léon Bérard Cancer Center); €19,850; 13 months
- REPA-ENVI Identification de signatures phénotypiques de réparation de l’ADN suite à l’exposition cellulaire à des carcinogènes environnementaux; Coordination: Sylvie SAUVAI (CEA); €19,600; 13 months
- RI scolaire Recherche-interventionnelle Représentations et Prévention des cancers en milieu scolaire; Coordination: Véronique REGNIER (Lucien Neuwirth Cancerology Institute); €41,300; 13 months

ONCOSTARTER - TRANSLATIONAL RESEARCH

- ZIRA ZNF217, nouveau marqueur pronostic et prédicatif du cancer du sein ER+; Coordination: Pascale COHEN (Cancer Research Center Lyon); €50,000; 13 months
- PanLOX Potentialisation des traitements des cancers du pancréas par inhibition de l’activité Lyssyl Oxidase; Coordination: David BERNARD (Cancer Research Center of Lyon); €50,000; 13 months
- NANO-CÔLON Développement de nanoparticules fluorescentes fonctionnalisées pour la détection des lésions tumorales colorectales; Coordination: Jean-Marc PHELIP (University of Saint-Etienne); €50,000, 13 months
## PROOF OF CONCEPT (ONGOING)

<table>
<thead>
<tr>
<th>Amount (k€)</th>
<th>Institute</th>
<th>Coordinator / Bénéficiaire</th>
<th>Industrial Partner</th>
<th>Geographical Area</th>
<th>Name of Project</th>
<th>Call for Projects</th>
<th>Length (Months)</th>
<th>Financing Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>633</td>
<td>Grenoble Institute of Neurosciences</td>
<td>François BERGER</td>
<td>Ecrins Therapeutics</td>
<td>Grenoble</td>
<td>CancerDrug</td>
<td>PdC 2009</td>
<td>39</td>
<td>Isère General Council, Grenoble Alpes Métropole, City of Grenoble,</td>
</tr>
<tr>
<td>627</td>
<td>Lyon Civil Hospitals</td>
<td>Marc COLOMBEL</td>
<td>ADEPT</td>
<td>Lyon</td>
<td>Doc_Calipso</td>
<td>PdC 2010</td>
<td>36</td>
<td>Rhône-Alpes Regional Council</td>
</tr>
<tr>
<td>140</td>
<td>Lyon Civil Hospitals</td>
<td>Thierry PONCHON</td>
<td>NESTIS</td>
<td>Lyon</td>
<td>Enki_HEH</td>
<td>PdC 2011</td>
<td>15</td>
<td>Rhône General Council, Greater Lyon</td>
</tr>
<tr>
<td>7</td>
<td>Albert Gonniot Institute</td>
<td>Joël PLUMAS</td>
<td>French Blood Agency</td>
<td>Grenoble</td>
<td>GeniusVac_Mel4</td>
<td>PdC 2011</td>
<td>48</td>
<td>ERDF, Grenoble Alpes Métropole, City of Grenoble</td>
</tr>
<tr>
<td>498</td>
<td>Léon Bérard Cancer Center</td>
<td>Patrice PEVERAT</td>
<td>Fluoptics</td>
<td>Lyon</td>
<td>Hepatofluo</td>
<td>PdC 2011</td>
<td>30</td>
<td>Rhône General Council, Rhône-Alpes Regional Council</td>
</tr>
<tr>
<td>535</td>
<td>INSERM</td>
<td>David MELODELIMA</td>
<td>EDAP TMS</td>
<td>Lyon</td>
<td>HIFU</td>
<td>PdC 2006</td>
<td>79</td>
<td>Greater Lyon</td>
</tr>
<tr>
<td>50</td>
<td>Cancer Research Center of Lyon</td>
<td>Charles DUMONTET</td>
<td>HLA-G Technologies</td>
<td>Lyon</td>
<td>HLA-G</td>
<td>PdC 2011</td>
<td>22</td>
<td>Greater Lyon, Rhône General Council</td>
</tr>
<tr>
<td>228</td>
<td>CNRS</td>
<td>Jean-Luc LENORMAND</td>
<td>Synthélis</td>
<td>Grenoble</td>
<td>Lipobak</td>
<td>PdC 2009</td>
<td>36</td>
<td>Isère General Council, Grenoble Alpes Métropole, City of Grenoble, ERDF</td>
</tr>
<tr>
<td>481</td>
<td>Cancer Research Center of Lyon</td>
<td>Christophe CAUX</td>
<td>ImmunID</td>
<td>Lyon, Grenoble</td>
<td>Lymphos1</td>
<td>PdC 2008</td>
<td>56</td>
<td>Rhône General Council</td>
</tr>
<tr>
<td>426</td>
<td>Atomic Energy Commission, LETI</td>
<td>Isabelle TExIER-NOGUES</td>
<td>Advanced Accelerated Application</td>
<td>Grenoble</td>
<td>Nano_Eno</td>
<td>PdC 2010</td>
<td>36</td>
<td>ERDF, Rhône-Alpes Regional Council</td>
</tr>
<tr>
<td>400</td>
<td>Léon Bérard Cancer Center</td>
<td>Servane TAUSZIG-DELMASURE</td>
<td>Netris-Pharma</td>
<td>Lyon</td>
<td>NT3_Target</td>
<td>PdC 2009</td>
<td>40</td>
<td>ERDF, Rhône General Council</td>
</tr>
<tr>
<td>751</td>
<td>Léon Bérard Cancer Center</td>
<td>Jean-Yves BLAY</td>
<td>Oncotherapy Science</td>
<td>Lyon</td>
<td>Synfrizz</td>
<td>PdC 2010</td>
<td>48</td>
<td>ERDF, Greater Lyon, Rhône General Council</td>
</tr>
<tr>
<td>354</td>
<td>Centre de Recherche en Cancérologie de Lyon, INSERM, CNRS</td>
<td>Jean-Jacques Diaz</td>
<td>iDD-Biotech</td>
<td>Lyon</td>
<td>Thera8</td>
<td>PdC 2011</td>
<td>36</td>
<td>Rhône General Council, Greater Lyon</td>
</tr>
<tr>
<td>416</td>
<td>Cancer Research Center of Lyon, INSERM, CNRS</td>
<td>Elisabeth MIOT-NOIRAULT</td>
<td>Cyclopharma</td>
<td>Clermont-Ferrand</td>
<td>TRT_PETMEL</td>
<td>PdC 2008</td>
<td>48</td>
<td>ERDF, Auvergne Regional Council, Puy de Dôme General Council, Clermont Community</td>
</tr>
<tr>
<td>278</td>
<td>VetAgroSup, EPSP</td>
<td>Claude CARROZO</td>
<td>A-Surgical</td>
<td>Lyon</td>
<td>UroLink</td>
<td>PdC 2011</td>
<td>24</td>
<td>Greater Lyon, Rhône General Council</td>
</tr>
</tbody>
</table>
Appendix 1

**ITMO CANCER 2012**

**Support for Training in Translational Cancer Research**
- Traitement par anticorps monoclonaux des leucémies à cellules dendritiques plasmocytoides; Coordination: Amélie BOESPFLUG (UMR 5286, Cancer Research Center of Lyon); €33,732; 12 months
- Rôle du microARN mir-9 et de son réseau génique dans le développement tumoral des glioblastomes; Coordination: Amandine BRUYAS (U1028 UMR 5292, Neurosciences Research Center, Lyon); €32,000; 12 months
- Study of genomic instability and telomere status in triple-negative breast cancer; Coordination: Mathilde GAY-BELLILÉ (Laboratory of Medical Cytogenetics, Clermont-Ferrand); €123,000; 36 months

**Research Projects in Effects of Exposure to Environmental Risks**
- Genotoxicity of diesel engines emission: an in vivo study under controlled conditions; Coordination: Thierry DOUKI (LCIB UMR E3 CEA/UJF, Grenoble); €44,281; 24 months

**Support for Mathematical and Statistical Sciences applied to Cancer Research**
- Analysis of social and geographical disparities in net survival using FLEXible frailty survival models; Coordination: Nadine BOSSARD (Lyon Civil Hospitals)

**Models of Animal Spontaneous Tumors for Translational Cancer Research**
- Lepidic pulmonary adenocarcinomas: from sheep to human; Coordination: Caroline LEROUX (UMR754 INRA-UCBL1, Lyon); €392,400; 36 months

**Research Projects in Physics, Mathematics or Engineering Sciences applied to Cancer**
- Impact of physical constraints on cancer stem cell resistance; Coordination: Françoise ARGOUL (UMR 5672 Laboratory of Physics, ENS, Lyon); €230,260
- Développement d’une matrice de chambers d’ionisation pour la mesure en 2D des faisceaux en radiothérapie à modulation d’intensité, pendant le traitement et en amont du patient; Coordination: Yannick ARNOUD (UMR5821 Laboratory of Subatomic Physics and Cosmology, Grenoble); €223,077; 24 months
- Design and test of a verification method of the 3D dose distribution delivered by radiotherapy beams using a new 3D chemical dosimeter, Dosi3D; Coordination: Véronique DEDIEU (EA 3846 Clermont-Ferrand); €240,237; 24 months
- Modélisation mathématique de la réponse des gliomes de bas-grade aux chimiothérapies et radiothérapie; Coordination: Benjamin RIBBA (INRIA, Saint-Ismier); €110,897; 24 months

**Support for Mathematical and Statistical Sciences applied to Cancer**
- Functional annotation of the transcriptome at the exon level; Coordination: Didier AUBOEUF (U1052 Léon Bérard Cancer Center, Lyon); €295,319,58; 36 months

**CLIPP: Certificated Centers of early Clinical Studies**
- Cancer de la tête et du cou; Coordination: Jérôme FAYETTE (Léon Bérard Cancer Center, Lyon); €766,000; 30 months

**Translational Cancer Research**
- Marquage isotopique chez les patients atteints de gliomes à l’aide d’acides aminés marqués au carbone 13; Coordination: François BERGER (CHU Grenoble); €557,919; 24 months
- Radiothérapie interne vectorisée pour le traitement du mélanome; Coordination: Jean-Michel CHEZAL (CHU Clermont-Ferrand); €461,549; 36 months

**Interventional Research aiming at Reducing the Social Inequalities in Cancer**
- ColoNav. Navigateur de patients pour le dépistage du cancer colorectal. Étude d’intervention dans des zones défavorisées; Coordination: Franck CHAUVIN (Lyon Cancer Institute, Saint-Étienne); €664,400; 36 months

**PAIR Gynaecological Cancers**
- Les récepteurs à dépendance, une nouvelle cible pour les cancers gynécologiques; Coordination: Agnès BERNET (Léon Bérard Cancer Center, Lyon); €750,000; 48 months

**Free Research Projects on Health and Safety, Epidemiology and Public Health**
- Biomarqueurs en vitamines B, Épigénome, polymorphismes génétiques et risque de cancer du sein dans la cohorte EPIC (European Prospective Investigation into Cancer and Nutrition); Coordination: Isabelle ROMIEU (IARC, Lyon); €650,000; 24 months
- Surdiagnostic lié au dépistage du cancer du sein par mammographie dans le département de l’Isère au cours de la période 2007 – 2010; Coordination: Arnaud SEIGNEURIN (Joseph Fourier University, Grenoble); €150,000, 24 months
- Rôle des inégalités sociales et territoriales dans la prise en charge des patients atteints de sarcomes éligibles à un traitement en hadronthérapie en région Rhône-Alpes: étude des facteurs épidémiologiques, accès et filières de soins et impact sur la survie à partir d’une cohorte exhaustive initiée en 2005; Coordination: Stéphanie PATIN (GCS ETOILE, Lyon); €122,011; 24 months

**Public Health: Support for Studies and Actions to improve Prevention and Screening for Cancers**
- Amélioration de l’accès au dépistage des cancers du col utérin des populations fragilisées en Isère; Coordination: Ouarda BEZAZ (Office of the Fight against Cancer, Meylan); €68,350; 24 months
- Dépistage des cancers et inégalités, mutualisation régionale ; Coordination: Marie-Ange GRONDIN (Interdepartmental Bourbonnaise organization for Cancer detection, Moulins); €94,272; 24 months

**Associations and Quality of Life**
- Gym’Après Cancer; Coordination: Dominique TOUATI (Auvergne exercise and volunteer gymnastics regional committees, Clermont-Ferrand); €55,000; 24 months

More info on [www.canceropole-clara.com](http://www.canceropole-clara.com)
Support for Innovative and Costly Techniques (STIC)
- Comparaison lymphadénectomie pelvienne versus prélèvement isolé du ganglion sentinel dans les cancers précoces du col utérin: étude multicentrique randomisée avec évaluation des impacts médico-économiques; Coordination: Patrice MATHEVET (Woman-Mother-Child Hospital, Lyon); €78,000; 24 months

Clinical Research Hospital Program (PHRC)
- NEPHA: Étude prospective, randomisée, multicentrique, comparant la Nutrition Entérale et la nutrition Parentérale comme support nutritionnel chez les malades atteints d'Hématopie maligne traités par Allogreffe de cellules souches hématoïdriques; Coordination: Corinne BOUTELOUP (CHU Clermont-Ferrand); €335,000; 48 months
- Randomized, open label, multicentric phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with poor prognosis, ER+ and HER2- primary breast cancer who remain free of disease after receiving 2 to 3 years of adjuvant hormone therapy; Coordination: Thomas BACHELOT (Léon Bérard Cancer Center, Lyon); €902,000; 48 months
- A phase III, randomized, multicenter trial comparing interruption or maintenance of imatinib after 3 years of treatment as adjuvant therapy in the treatment of Gastrointestinal Stromal Tumor (GIST); Coordination: Jean-Yves BLAY (Léon Bérard Cancer Center, Lyon); €400,000; 48 months
- Étude de phase II randomisée évaluant l’efficacité et la tolérance du cetuximab dans le cancer de la verge métastatique; Coordination: Hélène BOYLE (Léon Bérard Cancer Center, Lyon); €293,000; 48 months
- Stereotactic radiotherapy for paediatric recurrent intracranial ependymomas after previous radiation therapy; Coordination: Christian CARRIE (Léon Bérard Cancer Center, Lyon); €390,000; 48 months
- Identification of GENEtic markers of aggressiveness by comparative genomic analysis (CGH); Coordination: Gérald GUESQUIERE (Léon Bérard Cancer Center, Lyon); €213,000; 48 months

- Étude prospective internationale de comparant 3 schémas d’administration de carboplatine +/- paclitaxel chez la patiente âgée vulnérable atteinte de cancer de l’ovaire avancé stades IIIB-IV. Une collaboration entre le GINECO (Groupe d’Investigateurs Nationaux pour l’Étude des Cancers de l’Ovaire et du sein) et le GCIG (Gynecologic Cancer Intergroup); Coordination: Claire FALANDRY (CHU Lyon-Sud, Lyon); €403,000; 36 months
- Prospective trial for the diagnosis and treatment of children, adolescents and young adults with intracranial ependymoma Coordination: Didier FRAPPAZ (Léon Bérard Cancer Center, Lyon); €342,000; 48 months
- Étude multicentrique de phase II évaluant le conditionnement BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) suivi d’une autogreffe de cellules souches périphériques en traitement de consolidation des premières et secondes rechutes chimiosensibles pour des patients porteurs de lymphomes folliculaires; Coordination: Hervé GUESQUIERE (Léon Bérard Cancer Center, Lyon); €303,000; 48 months
- Étude de phase III évaluant chez des patients atteints de cancer bronchique non a petites cellules métastatiques contrôlées après chimiothérapie d’induction par ciplatine + gemcitabine le maintien du contrôle de la maladie par la poursuite de la gemcitabine en maintenance ou par l’introduction séquentielle de l’erlotinib (Tarceva); Coordination: Maurice PEROL (Croix-Rousse Hospital, Lyon); €73,000; 48 months
- High-Intensity Focused Ultrasound (HIFU)-Assisted Hepatic Resection; Coordination: Michel RIVOIRE (Léon Bérard Cancer Center, Lyon); €146,000; 48 months

Development of Housing close to Medical Care Centers
- Création d’un parc d’appartements thérapeutiques; Coordination: Jean-Robert GRESLIN (Léon Bérard Cancer Center, Lyon); €205,000; 36 months

Certification of French Intergrups of International Dimensions Collaborators in Cancer
- Intergroupes LYSA-LYSARC; Coordination: Gilles SALLES (LYSA - The Lymphoma Study Association, Lyon); €100,000; 24 months

Multidisciplinary Care of People hereditarily predisposed to Cancer
- Oncogéneauvergne; Coordination: Yves-Jean BIGNON (Jean PERRIN Cancer Center, Clermont-Ferrand); €200,000; 12 months
- Organisation de la prise en charge multidisciplinaire des personnes prédisposées héréditairement aux cancers fréquents (sein, côlon) dans la Région Rhône-Alpes; Coordination: Valène BONADONA (Léon Bérard Cancer Center, Lyon); €360,000; 12 months
# THE LEAGUE AGAINST CANCER

## TEAM ACCREDITED 2012

<table>
<thead>
<tr>
<th>Name</th>
<th>Year of Accreditation</th>
<th>Name of Project</th>
<th>Institution</th>
<th>Institution cont’d.</th>
<th>City</th>
<th>Amount €</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corinne ALBIGES-RIZO</td>
<td>3rd year</td>
<td>Promotion of invasion by a switch or coordination between focal adhesions and invadopodia</td>
<td>INSERM U 823, Albert Bonniot Institute</td>
<td>Grenoble</td>
<td></td>
<td>120,000</td>
</tr>
<tr>
<td>Claude COCHET</td>
<td>3rd year</td>
<td>Protéine-kinase CK2 et cancers. Optimisation et évaluation pré-clinique de l’activité anti-cancéreuse de nouveaux inhibiteurs chimiques</td>
<td>INSERM U 873 - CEA Grenoble, iRSTV, TS, Technology Research Institute</td>
<td>Grenoble</td>
<td></td>
<td>95,000</td>
</tr>
<tr>
<td>Attilio DI PIETRO</td>
<td>1st year</td>
<td>Caractérisation pluridisciplinaire des transporteurs ABC de cellules cancéreuses chimiorésistantes : mécanisme moléculaire et cellulaire, et nouvelles stratégies de modulation in vivo, in vitro et in silico</td>
<td>CNRS UMR 5086, Protein Biology and Chemistry Institute</td>
<td>Lyon</td>
<td></td>
<td>95,000</td>
</tr>
<tr>
<td>Stefan DIMITROV</td>
<td>2nd year</td>
<td>Histone variants, epigenetics and cancer</td>
<td>INSERM U 823, Albert Bonniot Institute</td>
<td>Grenoble</td>
<td></td>
<td>60,000</td>
</tr>
<tr>
<td>Patrick MEHLEN</td>
<td>1st year</td>
<td>La notion des récepteurs à dépendance : du concept de biologie cellulaire au développement de nouvelles thérapeutiques ciblées anti-cancéreuses</td>
<td>INSERM U 1052, Léon Bérard Cancer Center</td>
<td>Lyon</td>
<td></td>
<td>150,000</td>
</tr>
<tr>
<td>François MORLE</td>
<td>3rd year</td>
<td>Décryptage des réseaux de régulation géniques impliqués dans le contrôle de la prolifération et de la différenciation de la lignée érythrocytaire normale ou leucémique</td>
<td>CNRS UMR 5534, Claude Bernard - Lyon I University</td>
<td>Villeurbanne</td>
<td></td>
<td>66,000</td>
</tr>
<tr>
<td>Alain PUISIEUX</td>
<td>2nd year</td>
<td>Étude du rôle joué par la réactivation de programmes embryonnaires dans la transformation néoplasique</td>
<td>INSERM U 590, Léon Bérard Cancer Center</td>
<td>Lyon</td>
<td></td>
<td>150,000</td>
</tr>
</tbody>
</table>

## CLINICAL RESEARCH REGIONAL PLATFORM 2012

<table>
<thead>
<tr>
<th>Name</th>
<th>Type of Grant</th>
<th>Name of Project</th>
<th>Institution</th>
<th>Institution Cont’d.</th>
<th>City</th>
<th>Amount €</th>
</tr>
</thead>
<tbody>
<tr>
<td>David PEROL</td>
<td>Clinical Research</td>
<td>Plate-forme d’Aide à la Recherche Clinique en Cancérologie Auvergne et Rhône-Alpes</td>
<td>Biostatistics and therapeutic evaluation unit</td>
<td>Léon Bérard Cancer Center</td>
<td>Lyon</td>
<td>120,000</td>
</tr>
</tbody>
</table>

## PROJET DE RECHERCHE CLINIQUE 2012

<table>
<thead>
<tr>
<th>Name</th>
<th>Year of Financing</th>
<th>Name of Project</th>
<th>Institution</th>
<th>Institution Cont’d.</th>
<th>City</th>
<th>Amount €</th>
</tr>
</thead>
<tbody>
<tr>
<td>Franck CHAUVIN</td>
<td>1st year</td>
<td>ColoNav Étude interventionnelle de Navigation pour augmenter la participation au dépistage organisé du cancer colorectal dans les zones défavorisées. Évaluation du dispositif dans 5 départements français</td>
<td>CIC-EC 3 - Equipe PREDUCAN, Loire Cancer Institute</td>
<td>Saint-Priest-en Jarez</td>
<td></td>
<td>100,000</td>
</tr>
</tbody>
</table>
RESEARCH PROJECTS IN HUMAN AND SOCIAL SCIENCES 2012

<table>
<thead>
<tr>
<th>Name</th>
<th>Year of Financing</th>
<th>Name of Project</th>
<th>Institution</th>
<th>Institution cont’d.</th>
<th>City</th>
<th>Amount  €</th>
</tr>
</thead>
<tbody>
<tr>
<td>Claire FALANDRY</td>
<td>1st year</td>
<td>Essai PROACTIVE (PRogramme Observance ACTIVité Vitamines Equilibre) : étude de l’impact d’une intervention gériatrique associant activité physique régulière et suivi médical et nutritionnel sur l’observance du traitement hormonal adjuvant du cancer du sein après 70 ans</td>
<td>CNRS UMR 5239</td>
<td>South Lyon Faculty of Medicine</td>
<td>Oullins</td>
<td>50,000</td>
</tr>
<tr>
<td>Anne LEFRANC</td>
<td>3rd year</td>
<td>Étude contrôlée randomisée évaluant chez des femmes atteintes d’un cancer du sein métastatique l’impact d’une concertation systématisée « oncologues - équipe de soins de support » sur le recours à une ligne de chimiothérapie supplémentaire</td>
<td>Centre Léon Bérard</td>
<td>Lyon</td>
<td>19,000</td>
<td></td>
</tr>
<tr>
<td>Nora MOUMJID</td>
<td>2nd year</td>
<td>Structures de proximité versus plateaux techniques en Cancérologie : analyse organisationnelle et des préférences des patients</td>
<td>CNRS UMR 5824</td>
<td>Léon Bérard Cancer Center</td>
<td>Lyon</td>
<td>55,000</td>
</tr>
</tbody>
</table>

RESEARCH ALLOCATIONS 2012 (DETAILS AVAILABLE ON REQUEST)

- 27 thesis allocations in the amount of €801,162
- 5 post-doctoral allocations in the amount of €261,523
- 2 ATIP/AVENIR programs in the amount of €120,000

ARC FOUNDATION FOR RESEARCH ON CANCER

FINANCING IN PARTNERSHIP

- Dependence receptors as new therapeutic targets for gynecological cancers; Coordination: Agnès BERNET (Cancer Research Center of Lyon); €250,000; 48 months
- Fonctionnement CLIP²; Léon Bérard Cancer Center; €34,285,71; 12 months
- Fonctionnement CLIP²; Jean Perrin Cancer Center; €22,857,14; 12 months
- Fonctionnement CLIP²; South Lyon Hospital Center; €11,428,57; 12 months
- Essai clinique (BKM) (Léon Bérard Cancer Center); €383,773,50; 42 months

THEMATIC CALL FOR PROJECTS

- NEOZOL – Comparative Study of Neoadjuvant Chemotherapy with and without Zometa® for Management of Locally Advanced Breast Cancers; Coordination: Patrice MATHEVET/ Philippe CLEZARDIN (Woman-Mother-Child Hospital, Lyon); €166,488; 24 months

ARC CLASSIC FINANCING (DETAILS AVAILABLE ON REQUEST)

- 30 allocations to young researchers in the amount of €1,377,846
- 9 ARC projects in the amount of €450,000
- 2 semi-heavy equipments in the amount of €507,000

ANR

<table>
<thead>
<tr>
<th>Type</th>
<th>Coordinator (Institution)</th>
<th>Geographical Area</th>
<th>Name of Project</th>
<th>Amount</th>
<th>Length</th>
</tr>
</thead>
<tbody>
<tr>
<td>RPIB</td>
<td>Jérémy BASTID (OregaBiotech)</td>
<td>Lyon</td>
<td>Orega-17 (développement de nouveaux antagonistes d’IL-17 en Oncologie)</td>
<td>n.c.</td>
<td>n.c.</td>
</tr>
<tr>
<td>RPIB</td>
<td>Pascal PERRIAT (INSA)</td>
<td>Lyon</td>
<td>Multimage (structures nanométriques pour détection précoce en imagerie multimodale)</td>
<td>n.c.</td>
<td>n.c.</td>
</tr>
</tbody>
</table>
## INVESTMENTS OF THE FUTURE

<table>
<thead>
<tr>
<th>Type</th>
<th>Coordinator</th>
<th>CLARA Actor Involved</th>
<th>Geographical Area</th>
<th>Name of Project</th>
<th>Amount €M</th>
<th>Program Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>LABEX</td>
<td>PRES Université de Grenoble</td>
<td>PRES University of Grenoble</td>
<td>Strasbourg, Brest, Rennes, Paris, Montpellier, Grenoble</td>
<td>CAMI</td>
<td>7,5</td>
<td>New approaches for medical interventions assisted by computer (cancer and others)</td>
</tr>
<tr>
<td>LABEX</td>
<td>University of Lyon</td>
<td>CREATIS, IPNL, LIRIS, LHC, LPC, CRNL, CEA LETI, LPCML, INAC, LIP, LRCM, LPSC, Neurodis Foundation</td>
<td>Clermont-Ferrand, Saint-Étienne, Grenoble, Lyon</td>
<td>PRIMES</td>
<td>8</td>
<td>Development of methods and innovative products in medical imaging for the localization of tumors and to improve treatment</td>
</tr>
<tr>
<td>Equipex</td>
<td>University of Lyon</td>
<td>GIE CERMEP, CREATIS, CRNL, CarMeN, Neurodis Foundation, Siemens Healthcare, Lyon Civil Hospitals</td>
<td>Bron (Lyon), Saint-Étienne</td>
<td>LILI</td>
<td>4</td>
<td>Innovative imaging platform constituted of a tomography hybrid system and magnetic resonance imaging for structural and functional exploration</td>
</tr>
<tr>
<td>Equipex</td>
<td>University of Lyon</td>
<td>CRCL, CRNL, CarMeN, SFR Biosciences Gerland-Lyon Sud, SFR Health East Lyon, Netris Pharma, Functional Genomics Institute of Lyon, Nutrition and Brain</td>
<td>Lyon, Saint-Étienne</td>
<td>PhenoCan</td>
<td>2,7</td>
<td>Development of cancer models in mice platform</td>
</tr>
<tr>
<td>Nanobiotechnologies 2</td>
<td>CEA-LETI</td>
<td>CEA-LETI</td>
<td>Grenoble</td>
<td>FACSBIOMARKER</td>
<td>1,1</td>
<td>Exploration of nanotechnologies potential for the development of new and less invasive high resolution diagnostics methods in Oncology</td>
</tr>
<tr>
<td>National Infrastructures of biology and health research</td>
<td>CEA</td>
<td>Lyon and Grenoble Medical Imaging platforms</td>
<td>Grenoble, Lyon et territoire national</td>
<td>FLI</td>
<td>37,6</td>
<td>National infrastructure regrouping six major imaging platforms for preclinical and clinical imaging research including the archival storage and treatment of images</td>
</tr>
<tr>
<td>National Infrastructures of biology and health research</td>
<td>ESTEAM PARIS SUD, INSERM</td>
<td>N/A</td>
<td>Lyon, Evry, Villejuif, Strasbourg, Montpellier</td>
<td>INGESTEM</td>
<td>14</td>
<td>Setting-up of a unique stem cell biobank with a therapeutic vocation and to structure this network around an industrial cluster</td>
</tr>
<tr>
<td>Carnot Institute International</td>
<td>Carnot CALYM Institute</td>
<td>GELARC, GELA, ENS Lyon, Lyon Civil Hospitals</td>
<td>Lyon and national territory</td>
<td>CALYM</td>
<td>14</td>
<td>Consortium for the acceleration of innovation and is transfer in the field of lymphoma</td>
</tr>
</tbody>
</table>

More info on [www.canceropole-clara.com](http://www.canceropole-clara.com)
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Thematic</th>
<th>Title of Project</th>
<th>Project Leader</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIBA</td>
<td>Nanotechnologies/ Nanomédecine</td>
<td>Delivering Nanopharmaceuticals through Biological Barriers</td>
<td>Patrick BOISSEAU</td>
<td>Atomic Energy Commission (CEA), Grenoble</td>
</tr>
<tr>
<td>Bone-Net</td>
<td>PhD Training Network/Postdocs</td>
<td>European Training Network on Cancer-Induced Bone Diseases</td>
<td>Philippe CLEZARDIN</td>
<td>Claude Bernard Lyon 1 University</td>
</tr>
<tr>
<td>CD44 Carcinogenesis</td>
<td>Basic Research</td>
<td>A new role for CD44 in Carcinogenesis</td>
<td>Serge MANIÉ</td>
<td>Cancer Research Center of Lyon</td>
</tr>
<tr>
<td>DECanBio</td>
<td>Biomarqueurs/Diagnostic/ Pronostic</td>
<td>Novel MS-Based strategies to Discover and Evaluate Cancer Biomarkers in urine: Application to Diagnosis of Bladder Cancer</td>
<td>Jérôme GARIN</td>
<td>Atomic Energy Commission (CEA), Grenoble</td>
</tr>
<tr>
<td>EUROSARC</td>
<td>Clinical Research</td>
<td>European Clinical Trials in Rare Sarcomas within an integrated translational trial network</td>
<td>Jean-Yves BLAY</td>
<td>Cancer Research Center of Lyon</td>
</tr>
<tr>
<td>iNanoDCs</td>
<td>Nanotechnologies/ Nanomédecine</td>
<td>Design of multifunctional nanoparticles targeting TLR or Nod receptors for dendritic cell immune therapy</td>
<td>Bernard VERRIER</td>
<td>CNRS, IBCP, Lyon</td>
</tr>
<tr>
<td>NOTCH3DR</td>
<td>Basic Research</td>
<td>Investigating a novel role of Notch3 as a dependence receptor and its relevance in vivo</td>
<td>Patrick MELHEN</td>
<td>Cancer Research Center of Lyon</td>
</tr>
<tr>
<td>TARGET-PDT</td>
<td>Nanotechnologies/ Nanomédecine</td>
<td>PhotoDynamic Therapy using photosensitizer-doped targeted organic nanoparticles</td>
<td>Patrick BOISSEAU</td>
<td>Atomic Energy Commission (CEA), Grenoble</td>
</tr>
</tbody>
</table>
## Appendix 1

### PROJECTS INVOLVING THE CANCEROPOLE CLARA

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Thématique</th>
<th>Thematic</th>
<th>Project Leader</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>APO-SYS</td>
<td>Basic Research</td>
<td>Apoptosis systems biology applied to cancer and AIDS. An integrated approach of experimental biology, data mining, mathematical modeling, biostatistics, systems engineering and molecular medicine</td>
<td>Patrick MELHEN</td>
<td>Cancer Research Center of Lyon</td>
</tr>
<tr>
<td>ChinaAcces-s4EU</td>
<td>International Collaborations</td>
<td>Supporting the EU access to Chinese Research and Innovation Programmes</td>
<td>Jean-Luc COLL</td>
<td>Joseph Fourier Grenoble 1 University</td>
</tr>
<tr>
<td>COGS</td>
<td>Cancer Environnement</td>
<td>Collaborative Oncological Gene-environment Study</td>
<td>Olga SINILNIKOVA</td>
<td>Cancer Research Center of Lyon</td>
</tr>
<tr>
<td>CURELUNG</td>
<td>Biomarqueurs/Diagnostic/ Pronostic</td>
<td>Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis</td>
<td>Elisabeth BRAMBILLA</td>
<td>Joseph Fourier Grenoble 1 University</td>
</tr>
<tr>
<td>ENCCA</td>
<td>Access to therapy/treatment</td>
<td>European Network for cancer Research in Children and Adolescents</td>
<td>Olaf KELM, Liliana VEIRA</td>
<td>International Agency for Research on Cancer, Lyon Léon Bérard Cancer</td>
</tr>
<tr>
<td>ENVISION</td>
<td>Hadronthérapie</td>
<td>European NoVel Imaging Systems for ION therapy</td>
<td>Alain BALDIT, Daniel BABOT</td>
<td>CNRS, Clermont-Ferrand</td>
</tr>
<tr>
<td>Ethentec</td>
<td>Human and Social Sciences/Care</td>
<td>Ethics of enhancement technology</td>
<td>François BERGER</td>
<td>INSERM, CHU GIN, Grenoble</td>
</tr>
<tr>
<td>HEPACUTE</td>
<td>Basic Research</td>
<td>Host and viral factors in acute hepatitis C</td>
<td>Fabien ZOULIM</td>
<td>Cancer Research Center of Lyon</td>
</tr>
<tr>
<td>NANOSTEM</td>
<td>Nanotechnologies/ Nanomédecine</td>
<td>Targeting Combined Therapy to Cancer Stem Cells</td>
<td>Patrick BOISSEAU</td>
<td>Atomic Energy Commission (CEA), Grenoble</td>
</tr>
<tr>
<td>PROLIFICA</td>
<td>Prevention</td>
<td>Prevention of Liver Fibrosis and Cancer in Africa</td>
<td>Pierre HAINAUT, Fabien ZOULIM</td>
<td>International Agency for Research on Cancer, Lyon Cancer Research Center of Lyon</td>
</tr>
<tr>
<td>SPIDIA</td>
<td>Biomarqueurs/Diagnostic/ Pronostic</td>
<td>Standardisation and improvement of genetic pre-analytical tools and procedures for in vitro diagnostics</td>
<td>Pierre HAINAUT</td>
<td>International Agency for Research on Cancer, Lyon</td>
</tr>
<tr>
<td>ULICE</td>
<td>Hadronthérapie</td>
<td>Union of Light-Ion Centres in Europe</td>
<td>Jacques BALOSSO</td>
<td>CGS ÉTOILE, Lyon</td>
</tr>
</tbody>
</table>

More info on [www.cancerpole-clara.com](http://www.cancerpole-clara.com)
## SUMMARY OF CLARA’S MULTI-YEAR SCHEDULING
### 2003-2012

Breakdown of key funding by program and by source

<table>
<thead>
<tr>
<th></th>
<th>2012 Budget (€K)</th>
<th>2003-2011 Budget (€K)</th>
<th>Total (€K)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Investment</td>
<td>Operations</td>
<td>Investment</td>
</tr>
<tr>
<td>Platforms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Auvergne Platform</td>
<td>Approved 1,653</td>
<td>Paid 1,653</td>
<td>Approved 2,180</td>
</tr>
<tr>
<td>CIRC Platform</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grenoble Platform</td>
<td>Approved 4,171</td>
<td>Paid 4,171</td>
<td>Approved 12,459</td>
</tr>
<tr>
<td>East Lyon CLB Platform</td>
<td>3,000</td>
<td>1,492</td>
<td>8,500</td>
</tr>
<tr>
<td>South and East Lyon Platform</td>
<td>9,459</td>
<td>9,459</td>
<td>19,850</td>
</tr>
<tr>
<td>RMN Hight Fields Platform</td>
<td>3,000</td>
<td>1,492</td>
<td>9,459</td>
</tr>
<tr>
<td>Saint-Étienne Platform</td>
<td>114</td>
<td>114</td>
<td>6,323</td>
</tr>
<tr>
<td>Total Platforms</td>
<td>3,114</td>
<td>1,606</td>
<td>49,865</td>
</tr>
<tr>
<td>Project Financing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INCa Calls for Projects</td>
<td>5,736</td>
<td>2,859</td>
<td>67,491</td>
</tr>
<tr>
<td>Proof of Concept</td>
<td>44</td>
<td>44</td>
<td>688</td>
</tr>
<tr>
<td>Structuring Projects</td>
<td>1,135</td>
<td>1,135</td>
<td>1,135</td>
</tr>
<tr>
<td>Total Financing of projects</td>
<td>5,780</td>
<td>2,902</td>
<td>69,314</td>
</tr>
<tr>
<td>Total Conventions externes</td>
<td>3,114</td>
<td>1,606</td>
<td>49,865</td>
</tr>
<tr>
<td>CLARA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ProCan I Axes</td>
<td>2,650</td>
<td>2,650</td>
<td>67,491</td>
</tr>
<tr>
<td>ProCan II Axes</td>
<td>633</td>
<td>633</td>
<td>543</td>
</tr>
<tr>
<td>Proof of Concept</td>
<td>1,330</td>
<td>523</td>
<td>9,261</td>
</tr>
<tr>
<td>Structuring Projects</td>
<td>150</td>
<td>100</td>
<td>400</td>
</tr>
<tr>
<td>Total Financing of projects</td>
<td>2,113</td>
<td>1,256</td>
<td>12,854</td>
</tr>
<tr>
<td>Animation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Application Framework</td>
<td>2,600</td>
<td>2,600</td>
<td>2,600</td>
</tr>
<tr>
<td>Funding Convention</td>
<td>82</td>
<td>-</td>
<td>8,812</td>
</tr>
<tr>
<td>ProCan 2007-2010</td>
<td>1,225</td>
<td>1,225</td>
<td>1,225</td>
</tr>
<tr>
<td>ProCan 2011-2013</td>
<td>609</td>
<td>609</td>
<td>522</td>
</tr>
<tr>
<td>Total Animation</td>
<td>1,541</td>
<td>1,172</td>
<td>13,167</td>
</tr>
<tr>
<td>Total Cancéropôle CLARA</td>
<td>3,654</td>
<td>2,428</td>
<td>26,021</td>
</tr>
<tr>
<td>Total</td>
<td>3,114</td>
<td>1,606</td>
<td>49,865</td>
</tr>
</tbody>
</table>

Global orientation of financing approved in 2003-2012

- **9%** Total Financing of CLARA Projects €14,967K
- **9%** Total CLARA Animation €14,708K
- **35%** Total Platforms €56,259K
- **47%** Total Financing External Convention Projects €75,094K

*Updated December 31, 2012*
## Summary of key funding by territory

<table>
<thead>
<tr>
<th>territory</th>
<th>2012 Budget (€K)</th>
<th>2003-2011 Budget (€K)</th>
<th>Total (€K)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Approved</td>
<td>Paid</td>
<td>Approved</td>
</tr>
<tr>
<td>National Level</td>
<td>14</td>
<td>14</td>
<td>6,978</td>
</tr>
<tr>
<td>Rhône-Alpes</td>
<td>3,100</td>
<td>1,592</td>
<td>2,287</td>
</tr>
<tr>
<td>Auvergne</td>
<td>169</td>
<td>169</td>
<td>1,653</td>
</tr>
<tr>
<td>Total</td>
<td>3,114</td>
<td>1,606</td>
<td>9,434</td>
</tr>
</tbody>
</table>

## Summary of key funding by source

<table>
<thead>
<tr>
<th>source</th>
<th>2012 Budget (€K)</th>
<th>2003-2011 Budget (€K)</th>
<th>Total (€K)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Approved</td>
<td>Paid</td>
<td>Approved</td>
</tr>
<tr>
<td>External Conventions</td>
<td>14</td>
<td>14</td>
<td>9,136</td>
</tr>
<tr>
<td>Platforms</td>
<td>5,736</td>
<td>2,859</td>
<td>67,491</td>
</tr>
<tr>
<td>INCa Calls for Projects</td>
<td></td>
<td></td>
<td>1,027</td>
</tr>
<tr>
<td>Structuring Projects</td>
<td></td>
<td></td>
<td>67,491</td>
</tr>
<tr>
<td>Total External Conventions</td>
<td>14</td>
<td>14</td>
<td>5,736</td>
</tr>
<tr>
<td>Cancéropôle CLARA</td>
<td>1,242</td>
<td>1,242</td>
<td>5,927</td>
</tr>
<tr>
<td>Proof of Concept</td>
<td>633</td>
<td>633</td>
<td>543</td>
</tr>
<tr>
<td>ProCan II Axes</td>
<td>609</td>
<td>609</td>
<td>2,834</td>
</tr>
<tr>
<td>Animation</td>
<td>350</td>
<td>143</td>
<td>1,644</td>
</tr>
<tr>
<td>Total Cancéropôle CLARA</td>
<td>412</td>
<td>143</td>
<td>2,142</td>
</tr>
<tr>
<td>Total</td>
<td>412</td>
<td>143</td>
<td>2,142</td>
</tr>
</tbody>
</table>

Updated December 31, 2012

More info on [www.canceropole-clara.com](http://www.canceropole-clara.com)

Appendix 2
### 2012 Budget (€K) vs. 2003-2011 Budget (€K) - Total (€K)

<table>
<thead>
<tr>
<th>Investment Operations</th>
<th>2012 Budget</th>
<th>2003-2011 Budget</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved</td>
<td>Paid</td>
<td>Approved</td>
<td>Paid</td>
</tr>
<tr>
<td><strong>External Conventions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Structuring Projects</td>
<td>108</td>
<td>108</td>
<td>108</td>
</tr>
<tr>
<td><strong>Total External Conventions</strong></td>
<td>108</td>
<td>108</td>
<td>108</td>
</tr>
<tr>
<td><strong>Cancéropôle CLARA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proof of Concept</td>
<td>37</td>
<td>37</td>
<td>37</td>
</tr>
<tr>
<td>Animation</td>
<td>216</td>
<td>216</td>
<td>216</td>
</tr>
<tr>
<td><strong>Total Cancéropôle CLARA</strong></td>
<td>253</td>
<td>253</td>
<td>253</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>361</td>
<td>361</td>
<td>361</td>
</tr>
</tbody>
</table>
### Appendix 2

#### 2012 Budget (€K) vs. 2003-2011 Budget (€K)

<table>
<thead>
<tr>
<th></th>
<th>2012 Budget</th>
<th>2003-2011 Budget</th>
<th>Total (€K)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Approved</td>
<td>Paid</td>
<td>Approved</td>
</tr>
<tr>
<td><strong>Investment Operations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>External Conventions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platforms</td>
<td>1,100</td>
<td>1,000</td>
<td>1,100</td>
</tr>
<tr>
<td><strong>Total External Conventions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1,100</td>
<td>1,000</td>
<td>1,100</td>
</tr>
<tr>
<td><strong>Cancéropôle CLARA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Animation</td>
<td>25</td>
<td>25</td>
<td>75</td>
</tr>
<tr>
<td><strong>Total Cancéropôle CLARA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>25</td>
<td>75</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>25</td>
<td>25</td>
<td>1,100</td>
</tr>
</tbody>
</table>

#### 2012 Budget (€K) vs. 2003-2011 Budget (€K)

<table>
<thead>
<tr>
<th></th>
<th>2012 Budget</th>
<th>2003-2011 Budget</th>
<th>Total (€K)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Approved</td>
<td>Paid</td>
<td>Approved</td>
</tr>
<tr>
<td><strong>Investment Operations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>External Conventions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platforms</td>
<td>1,716</td>
<td>530</td>
<td>1,716</td>
</tr>
<tr>
<td><strong>Total External Conventions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1,716</td>
<td>530</td>
<td>1,716</td>
</tr>
<tr>
<td><strong>Cancéropôle CLARA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Structuring Projects</td>
<td>100</td>
<td>100</td>
<td>400</td>
</tr>
<tr>
<td>Animation</td>
<td>25</td>
<td>25</td>
<td>100</td>
</tr>
<tr>
<td><strong>Total Cancéropôle CLARA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>125</td>
<td>125</td>
<td>500</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>125</td>
<td>125</td>
<td>1,716</td>
</tr>
</tbody>
</table>

#### 2012 Budget (€K) vs. 2003-2011 Budget (€K)

<table>
<thead>
<tr>
<th></th>
<th>2012 Budget</th>
<th>2003-2011 Budget</th>
<th>Total (€K)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Approved</td>
<td>Paid</td>
<td>Approved</td>
</tr>
<tr>
<td><strong>Investment Operations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>External Conventions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proof of Concept</td>
<td>150</td>
<td>106</td>
<td>150</td>
</tr>
<tr>
<td><strong>Total External Conventions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>150</td>
<td>106</td>
<td>150</td>
</tr>
<tr>
<td><strong>Cancéropôle CLARA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proof of Concept</td>
<td>200</td>
<td>155</td>
<td>400</td>
</tr>
<tr>
<td>Structuring Projects</td>
<td>50</td>
<td>-</td>
<td>50</td>
</tr>
<tr>
<td>Animation</td>
<td>45</td>
<td>45</td>
<td>45</td>
</tr>
<tr>
<td><strong>Total Cancéropôle CLARA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>-</td>
<td>245</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>50</td>
<td>-</td>
<td>305</td>
</tr>
</tbody>
</table>

#### 2012 Budget (€K) vs. 2003-2011 Budget (€K)

<table>
<thead>
<tr>
<th></th>
<th>2012 Budget</th>
<th>2003-2011 Budget</th>
<th>Total (€K)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Approved</td>
<td>Paid</td>
<td>Approved</td>
</tr>
<tr>
<td><strong>Investment Operations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>External Conventions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proof of Concept</td>
<td>100</td>
<td>80</td>
<td>100</td>
</tr>
<tr>
<td><strong>Total External Conventions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>80</td>
<td>100</td>
</tr>
<tr>
<td><strong>Cancéropôle CLARA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proof of Concept</td>
<td>75</td>
<td>23</td>
<td>286</td>
</tr>
<tr>
<td>Animation</td>
<td>15</td>
<td>15</td>
<td>45</td>
</tr>
<tr>
<td><strong>Total Cancéropôle CLARA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>90</td>
<td>38</td>
<td>331</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>90</td>
<td>38</td>
<td>431</td>
</tr>
<tr>
<td></td>
<td>2012 Budget (€K)</td>
<td>2003-2011 Budget (€K)</td>
<td>Total (€K)</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------</td>
<td>------------------------</td>
<td>------------</td>
</tr>
<tr>
<td></td>
<td>Investment</td>
<td>Operations</td>
<td>Investment</td>
</tr>
<tr>
<td></td>
<td>Approved</td>
<td>Paid</td>
<td>Approved</td>
</tr>
<tr>
<td><strong>External Conventions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proof of Concept</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total External Conventions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cancéropôle CLARA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proof of Concept</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Animation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Cancéropôle CLARA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2012 Budget (€K)</th>
<th>2003-2011 Budget (€K)</th>
<th>Total (€K)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Investment</td>
<td>Operations</td>
<td>Investment</td>
</tr>
<tr>
<td></td>
<td>Approved</td>
<td>Paid</td>
<td>Approved</td>
</tr>
<tr>
<td><strong>External Conventions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platforms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2012 Budget (€K)</th>
<th>2003-2011 Budget (€K)</th>
<th>Total (€K)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Investment</td>
<td>Operations</td>
<td>Investment</td>
</tr>
<tr>
<td></td>
<td>Approved</td>
<td>Paid</td>
<td>Approved</td>
</tr>
<tr>
<td><strong>External Conventions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platforms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Updated December 31, 2012*
### Appendix 2

#### 2012 Budget (€K) vs. 2003-2011 Budget (€K)

<table>
<thead>
<tr>
<th></th>
<th>Investment</th>
<th>Operations</th>
<th>Investment</th>
<th>Operations</th>
<th>Total (€K)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Approved</strong></td>
<td><strong>Paid</strong></td>
<td><strong>Approved</strong></td>
<td><strong>Paid</strong></td>
<td><strong>Approved</strong></td>
<td><strong>Paid</strong></td>
</tr>
<tr>
<td><strong>External Conventions Platforms</strong></td>
<td>235</td>
<td>235</td>
<td>948</td>
<td>948</td>
<td>1,183</td>
</tr>
<tr>
<td><strong>Proof of Concept</strong></td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td><strong>Total External Conventions</strong></td>
<td>235</td>
<td>235</td>
<td>998</td>
<td>998</td>
<td>1,233</td>
</tr>
<tr>
<td><strong>Animation</strong></td>
<td>80</td>
<td>80</td>
<td>365</td>
<td>365</td>
<td>445</td>
</tr>
<tr>
<td><strong>Total Cancéropôle CLARA</strong></td>
<td>80</td>
<td>80</td>
<td>365</td>
<td>365</td>
<td>445</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>80</td>
<td>80</td>
<td>235</td>
<td>235</td>
<td>1,363</td>
</tr>
</tbody>
</table>

#### 2012 Budget (€K) vs. 2003-2011 Budget (€K)

<table>
<thead>
<tr>
<th></th>
<th>Investment</th>
<th>Operations</th>
<th>Investment</th>
<th>Operations</th>
<th>Total (€K)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Approved</strong></td>
<td><strong>Paid</strong></td>
<td><strong>Approved</strong></td>
<td><strong>Paid</strong></td>
<td><strong>Approved</strong></td>
<td><strong>Paid</strong></td>
</tr>
<tr>
<td><strong>External Conventions Platforms</strong></td>
<td>25</td>
<td>25</td>
<td>75</td>
<td>75</td>
<td>100</td>
</tr>
<tr>
<td><strong>Proof of Concept</strong></td>
<td>18</td>
<td>18</td>
<td>26</td>
<td>26</td>
<td>44</td>
</tr>
<tr>
<td><strong>Total External Conventions</strong></td>
<td>18</td>
<td>18</td>
<td>25</td>
<td>25</td>
<td>101</td>
</tr>
<tr>
<td><strong>Animation</strong></td>
<td>15</td>
<td>15</td>
<td>70</td>
<td>70</td>
<td>85</td>
</tr>
<tr>
<td><strong>Total Cancéropôle CLARA</strong></td>
<td>15</td>
<td>15</td>
<td>70</td>
<td>70</td>
<td>85</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>33</td>
<td>33</td>
<td>25</td>
<td>25</td>
<td>171</td>
</tr>
</tbody>
</table>

#### 2012 Budget (€K) vs. 2003-2011 Budget (€K)

<table>
<thead>
<tr>
<th></th>
<th>Investment</th>
<th>Operations</th>
<th>Investment</th>
<th>Operations</th>
<th>Total (€K)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Approved</strong></td>
<td><strong>Paid</strong></td>
<td><strong>Approved</strong></td>
<td><strong>Paid</strong></td>
<td><strong>Approved</strong></td>
<td><strong>Paid</strong></td>
</tr>
<tr>
<td><strong>External Conventions Platforms</strong></td>
<td>160</td>
<td>160</td>
<td>90</td>
<td>90</td>
<td>250</td>
</tr>
<tr>
<td><strong>Proof of Concept</strong></td>
<td>26</td>
<td>26</td>
<td>80</td>
<td>80</td>
<td>106</td>
</tr>
<tr>
<td><strong>Total External Conventions</strong></td>
<td>26</td>
<td>26</td>
<td>160</td>
<td>160</td>
<td>356</td>
</tr>
<tr>
<td><strong>Cancéropôle CLARA Animation</strong></td>
<td>30</td>
<td>30</td>
<td>140</td>
<td>140</td>
<td>170</td>
</tr>
<tr>
<td><strong>Total Cancéropôle CLARA</strong></td>
<td>30</td>
<td>30</td>
<td>140</td>
<td>140</td>
<td>170</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>56</td>
<td>56</td>
<td>160</td>
<td>160</td>
<td>526</td>
</tr>
</tbody>
</table>

#### 2012 Budget (€K) vs. 2003-2011 Budget (€K)

<table>
<thead>
<tr>
<th></th>
<th>Investment</th>
<th>Operations</th>
<th>Investment</th>
<th>Operations</th>
<th>Total (€K)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Approved</strong></td>
<td><strong>Paid</strong></td>
<td><strong>Approved</strong></td>
<td><strong>Paid</strong></td>
<td><strong>Approved</strong></td>
<td><strong>Paid</strong></td>
</tr>
<tr>
<td><strong>External Conventions Platforms</strong></td>
<td>30</td>
<td>30</td>
<td>100</td>
<td>100</td>
<td>130</td>
</tr>
<tr>
<td><strong>Total External Conventions</strong></td>
<td>30</td>
<td>30</td>
<td>100</td>
<td>100</td>
<td>130</td>
</tr>
<tr>
<td><strong>Total Cancéropôle CLARA</strong></td>
<td>30</td>
<td>30</td>
<td>100</td>
<td>100</td>
<td>130</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>30</td>
<td>30</td>
<td>100</td>
<td>100</td>
<td>130</td>
</tr>
</tbody>
</table>

*Updated December 31, 2012*
THE CANCÉROPÔLE
LYON AUVERGNE
RHÔNE-ALPES
COORDINATION TEAM

PRESIDENCE
Prof Jean-Pierre CLAVERANNE
President, Léa & Napoléon Bullukian Foundation*
+33 4 72 52 93 34 | contact@bullukian.com

Prof Thierry PHILIP
President, Executive Committee
+33 4 78 78 28 00 | thierry.philip@lyon.unicancer.fr

Prof Véronique TRILLET-LENOIR
President, Management Committee
+33 4 78 86 43 15 | veronique.trillet-ienoir@chu-lyon.fr

DIRECTION
Amaury MARTIN, Ph.D
Secretary General
+33 4 37 90 17 17 | amartin@canceropole-clara.com

R&D PROJECTS
Ophélie PHILIPOT, Ph.D
Project Manager
+33 4 37 90 17 25 | ophilipot@canceropole-clara.com

Arnaud CUTIVET, Ph.D
Project Manager
+33 4 37 90 17 14 | acutivet@canceropole-clara.com

ADMINISTRATION
Valérie FOUR
Executive Assistant
+33 4 37 90 17 13 | vfour@canceropole-clara.com

Nora BOUHILA
Administrator
+33 4 37 90 17 18 | nbouhila@canceropole-clara.com

Sophy MARCHAND
Administrator
+33 4 37 90 17 12 | smarchand@canceropole-clara.com

Marie-Thérèse BALMONT
Administration Manager, Léa & Napoléon Bullukian
Foundation*
+33 4 72 52 93 34 | mt.balmont@bullukian.com

* The Léa & Napoléon Bullukian Foundation, recognized
as a public interest foundation, is CLARA’s parent
organization and its coordination team’s employer.

SCIENTIFIC ANIMATION
AND COMMUNICATION
Élise JACQUES
Project Manager
+33 4 37 90 17 24 | ejacques@canceropole-clara.com

Esokia RIDET
Assistant
+33 4 37 90 17 10 | eridet@canceropole-clara.com

* The Léa & Napoléon Bullukian Foundation, recognized
as a public interest foundation, is CLARA’s parent
organization and its coordination team’s employer.

Photo Credits: Fotolia, Elise JACQUES / Esokia RIDET Cancéropôle
CLARA, Hygée Center, Romain ETIENNE / ITEM, JLEONE-Greater Lyon

Photo: (left to right) Marie-Thérèse BALMONT, Nora BOUHILA, Elise
JACQUES, Arnaud CUTIVET, Véronique TRILLET-LENOIR, Amaury
MARTIN, Jean-Pierre CLAVERANNE, Valérie FOUR, Esokia RIDET

Progress Report 2012